TECTIN™ Phase IIb/III Interim Analysis Expected
December 20, 2005
Vancouver, BC (December 20, 2005) - WEX Pharmaceuticals Inc. ("WEX" or "the Company") is pleased to announce that it has completed enrollment and dosing of 50% of the patients in the Tectin™ Phase IIb/III clinical study. The Company is preparing an interim analysis which is expected to be completed in the first quarter of 2006.
This trial is a randomized double-blind placebo controlled study currently being conducted at 29 sites in Canada for patients suffering from moderate to severe inadequately controlled cancer-related pain. The primary objective of this study is to compare safety and efficacy of subcutaneous treatment of Tectin™ versus placebo in reducing the intensity of pain in up to 150 patients with cancer.
Additional sites in Chile, where the Company has recently completed an investigators meeting, will participate in the study starting in January with the target of dosing up to 40 patients.
The remaining enrollment and dosing of patients in the study is expected to be completed in June 2006.
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat moderate to severe acute and chronic pain, symptom pain relief associated with addiction withdrawal from opioid abuse and medicines designed for local anaesthesia. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.
Forward Looking Statements
This News Release contains forward-looking statements which may not be based on historical fact, including without limitation statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements.
The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
For additional information on our products, visit us at www.wexpharma.com or call Don Evans, V.P. Corporate Communications at 604-683-8880 or 1-800-722-7549.
